Valentin Duvauchelle

Dr. Valentin Duvauchelle

Umeå University, Umeå, Västerbotten, Sweden
orcid
PhD. in medicinal chemistry | Post-doctoral fellow at Umeå U...

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CMChaimae Majdi
Chaimae Majdi
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
Patrick MEFFREPatrick MEFFRE
Patrick MEFFRE
Zohra BenfoddaZohra Benfodda
Zohra Benfodda
Bacterial resistance development represents a serious threat to human health across the globe and has become a very serious clinical problem for many classes of antibiotics. Hence, there is a constant and urgent need for the discovery and development of new effective antibacterial agents to stem the emergence of resistant bacteria. 1,4-naphthoquinones are an important class of natural products and have been known for decades as a privileged scaffold in medicinal chemistry regarding their many biological properties. The significant biological properties of specific 1,4-naphthoquinones hydroxyderivatives have drawn the attention of researchers in order to find new derivatives with an optimized activity, mainly as antibacterial agents. Based on juglone, naphthazarin, plumbagin and lawsone moieties, structural optimization was realized with the purpose of improving the antibacterial activity. Thereupon, relevant antibacterial activities have been observed on different panels of bacterial strains including resistant ones. In this review, we highlight the interest of developing new 1,4-naphthoquinones hydroxyderivatives and some metal complexes as promising antibacterial agents alternatives. Here, we thoroughly report for the first time both the antibacterial activity and the chemical synthesis of four different 1,4-naphthoquinones (juglone, naphthazarin, plumbagin and lawsone) from 2002 to 2022 with an emphasis on the structure-activity relationship, when applicable.

3 June 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
Patrick MEFFREPatrick MEFFRE
Patrick MEFFRE
Zohra BenfoddaZohra Benfodda
Zohra Benfodda

29 August 2022 in Environmental Chemistry Letters
Verified
Journal Article
Closed access
PDF file
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
Patrick MEFFREPatrick MEFFRE
Patrick MEFFRE
Zohra BenfoddaZohra Benfodda
Zohra Benfodda

19 November 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
CMChaimae Majdi
Chaimae Majdi
DBDavid Bénimélis
David Bénimélis
CDCatherine Dunyach-Remy
Catherine Dunyach-Remy
Patrick MEFFREPatrick MEFFRE
Patrick MEFFRE
Zohra BenfoddaZohra Benfodda
Zohra Benfodda
Infections caused by drug-resistant bacteria are a serious threat to human and global public health. Moreover, in recent years, very few antibiotics have been discovered and developed by pharmaceutical companies. Therefore, there is an urgent need to discover and develop new antibacterial agents to combat multidrug-resistant bacteria. In this study, two novel series of juglone/naphthazarin derivatives (43 compounds) were synthesized and evaluated for their antibacterial properties against various clinical and reference Gram-positive MSSA, clinical Gram-positive MRSA, and clinical and reference Gram-negative bacteria E. coli and P. aeruginosa. These strains are of clinical importance because they belong to ESKAPE pathogens. Compounds 3al, 5ag, and 3bg showed promising activity against clinical and reference MSSA (MIC: 1–8 µg/ml) and good efficacy against clinical MRSA (MIC: 2–8 µg/ml) strains. 5am and 3bm demonstrated better activity on both MSSA (MIC: 0.5 µg/ml) and MRSA (MIC: 2 µg/ml) strains. Their MICs were similar to those of cloxacillin against clinical MRSA strains. The synergistic effects of active compounds 3al, 5ag, 5am, 3bg, and 3bm were evaluated with reference antibiotics, and it was found that the antibiotic combination with 3bm efficiently enhanced the antimicrobial activity. Compound 3bm was found to restore the sensitivity of clinical MRSA to cloxacillin and enhanced the antibacterial activity of vancomycin when they were added together. In the presence of 3bm, the MIC values of vancomycin and cloxacillin were lowered up to 1/16th of the original MIC with an FIC index of 0.313. Moreover, compounds 3al, 5ag, 5am, 3bg, and 3bm did not present hemolytic activity on sheep red blood cells. In silico prediction of ADME profile parameter results for 3bm is promising and encouraging for further development.

6 October 2022 in Environmental Chemistry Letters
Verified
Journal Article
Closed access
PDF file
MRMiyanou Rosales-Hurtado
Miyanou Rosales-Hurtado
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
DBDavid Bénimélis
David Bénimélis
MOMaya Ogawa-Okada
Maya Ogawa-Okada
NYNaofumi Yamamoto
Naofumi Yamamoto
Zohra BenfoddaZohra Benfodda
Zohra Benfodda

26 January 2023 in ChemMedChem
Verified
Journal Article
Open access
RGRayane Ghoteimi
Rayane Ghoteimi
ABAbdennour Braka
Abdennour Braka
CRCéline Rodriguez
Céline Rodriguez
ECEmeline Cros-Perrial
Emeline Cros-Perrial
Valentin DuvauchelleValentin Duvauchelle
Valentin Duvauchelle
SPSuzanne Peyrottes
Suzanne Peyrottes
Various series of 4,6-biaryl-2-thiopyridine derivatives were synthesized and evaluated as potential ecto-5’-nucleotidase (CD73) inhibitors. Two synthetic routes were explored and the coupling of 4,6-disubstituted 3-cyano-2-chloro-pyridines with selected thiols allowed us to explore the structural diversity. Somehow divergent results were obtained in biological assays on CD73 inhibition using either the purified recombinant protein or cell-based assays, highlighting the difficulty to target protein-protein interface on proteins existing as soluble and membrane-bound forms. Among the 18 new derivatives obtained, three derivatives incorporating morpholino substituents on the 4,6-biaryl-2-thiopyridine core were shown to be able to reverse the adenosine-mediated immune suppression on human T cells. The higher blockade efficiency was observed for 2-((3-cyano-4,6-bis(4-morpholinophenyl)pyridin-2-yl)thio)-N-(isoxazol-3-yl)acetamide (with total reversion at 100 µM) and methyl 2-((3-cyano-4,6-bis(4-morpholinophenyl)pyridin-2-yl)thio)acetate (with partial reversion at 10µM). Thus, this series of compounds illustrates a new chemotype of CD73 allosteric inhibitors.